Vanguard Group Inc. Sells 172,147 Shares of Alkermes plc $ALKS

Vanguard Group Inc. decreased its holdings in shares of Alkermes plc (NASDAQ:ALKS) by 0.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 18,007,364 shares of the company’s stock after selling 172,147 shares during the quarter. Vanguard Group Inc. owned about 0.11% of Alkermes worth $503,846,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ALKS. Assetmark Inc. grew its stake in shares of Alkermes by 933.8% in the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock worth $25,000 after buying an additional 747 shares in the last quarter. Johnson Financial Group Inc. purchased a new stake in shares of Alkermes during the 3rd quarter valued at about $31,000. Salomon & Ludwin LLC lifted its holdings in shares of Alkermes by 115.6% in the 4th quarter. Salomon & Ludwin LLC now owns 1,244 shares of the company’s stock valued at $35,000 after acquiring an additional 667 shares during the last quarter. Hantz Financial Services Inc. lifted its holdings in shares of Alkermes by 395.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after acquiring an additional 989 shares during the last quarter. Finally, Osaic Holdings Inc. grew its position in Alkermes by 56.4% in the second quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock worth $56,000 after acquiring an additional 701 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

Insider Activity

In other news, EVP David Joseph Gaffin sold 2,034 shares of the company’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.20, for a total value of $67,528.80. Following the transaction, the executive vice president directly owned 231,558 shares in the company, valued at approximately $7,687,725.60. This represents a 0.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $33.40, for a total transaction of $300,600.00. Following the completion of the transaction, the executive vice president directly owned 81,389 shares in the company, valued at $2,718,392.60. This represents a 9.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 39,102 shares of company stock valued at $1,265,090. 4.59% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Needham & Company LLC upped their price objective on Alkermes from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Wednesday. Truist Financial raised Alkermes to a “strong-buy” rating in a research report on Wednesday, March 25th. Wolfe Research began coverage on Alkermes in a report on Monday, February 23rd. They set an “outperform” rating and a $45.00 price target on the stock. Piper Sandler lowered their price target on Alkermes from $45.00 to $43.00 and set an “overweight” rating for the company in a research report on Tuesday, March 24th. Finally, UBS Group reaffirmed a “buy” rating on shares of Alkermes in a research note on Wednesday. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $44.71.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Q1 results beat expectations — Alkermes reported ($0.43) EPS vs. the consensus loss of ($0.57) and revenue of $392.9M vs. $363.3M expected; revenue was up ~28% year‑over‑year, supporting the stock move higher. Alkermes Q1 Earnings Release
• Positive Sentiment: Management highlighted LUMRYZ momentum on the earnings call as a key driver of commercial growth and reiterated product-level traction that underpins near‑term revenue strength. Alkermes Earnings Call: LUMRYZ Momentum Drives Growth
• Neutral Sentiment: The full earnings‑call transcript is available for investors who want line‑by‑line detail on guidance, cost drivers and commercial commentary. Useful for modeling assumptions and Q&A takeaways. Alkermes Q1 2026 Earnings Call Transcript
• Neutral Sentiment: Analyst/metric notes: Zacks and others highlight the beats on revenue and EPS and provide comparisons vs. estimates and year‑ago metrics — helpful context but largely reiterates reported results. ALKS Q1: Key Metrics vs Estimates (Zacks)
• Neutral Sentiment: Insider activity: an EVP sold ~2,034 shares under a pre‑arranged 10b5‑1 plan; small percentage impact and not an unusual liquidity event but worth noting. Insider Sale: David Joseph Gaffin
• Negative Sentiment: FY‑2026 guidance disappointed vs. consensus — Alkermes narrowed EPS guidance to roughly ($0.521)–($0.405), materially below the street’s ~($0.09) estimate; revenue guidance was trimmed to ~$1.7–1.8B (vs. consensus near $1.8B). This guidance gap is the main downside risk to the rally and may pressure forward estimates. Alkermes Reports First Quarter 2026 Financial Results

Alkermes Stock Performance

Shares of ALKS stock opened at $36.25 on Wednesday. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.56. The firm has a market capitalization of $6.03 billion, a P/E ratio of 25.35 and a beta of 0.31. The stock has a 50 day moving average price of $31.53 and a 200 day moving average price of $30.98.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings data on Saturday, February 14th. The company reported $0.29 EPS for the quarter. Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company had revenue of $384.55 million for the quarter. As a group, sell-side analysts forecast that Alkermes plc will post -0.69 EPS for the current year.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.